University of California San Francisco
Give to UCSFBlood test that is currently under development may flag concussion in CT-negative patients, enabling them to be evaluated for long-term complications.
Researchers discovered a scorpion toxin that targets the “wasabi receptor,” which they think it can be used as a tool for studying chronic pain and inflammation, and may eventually lead to the development of new kinds of non-opioid pain relievers.
In a paper researchers describe a technique that uses a special version of CRISPR developed at UCSF to systematically alter the activity of genes in human neurons generated from stem cells, the first successful merger of stem cell-derived cell types and CRISPR screening technologies.
Scientists identify faulty molecular recycling as potential driver of Alzheimer’s disease.
UCSF scientists show that Alzheimer’s disease directly attacks brain regions responsible for wakefulness during the day.
UCSF scientists have for the first time decoded spoken words and phrases in real time from the brain signals that control speech.
Since 2017, UCSF researchers Winston Chiong and Eddie Chang have led a collaborative neuroethics research project funded by the NIH.
Brain damage associated with MS specifically targets a common class of brain cells called projection neurons
The Susan and Bill Oberndorf Foundation has made a new commitment of $25 million to UCSF psychiatry and the neurosciences, bringing its total giving to "UCSF: The Campaign" to $50 million.
Using advanced technology, scientists have discovered an autoimmune disease that appears to affect men with testicular cancer.
Today, our understanding of glioma subtypes has expanded to include the molecular and genetic variants that can influence a tumor’s development, prognosis, and response to treatment.
A new study suggests that the human brain may maintain reserves of immature neurons throughout life, using these “Peter Pan” cells in a similar manner to the neurogenesis seen in other species
Unlike other gene mutations linked to autism, which are thought to alter brain development before birth, the newly identified changes in brain signaling may occur closer to the onset of autism symptoms in the first years of life.
Research identifies enzymes produced by two different bacterial species that work together to digest L-Dopa in the human gut. Blocking one of these bacterial enzymes could significantly boost the drug’s efficacy in these patients.